Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 10, 2004, Pages 2673-2676

  Boussard, Cyrille ^a   Klimkait, Thomas ^b   Mahmood, Naheed ^c   Pritchard, Martin ^d   Gilbert, Ian H ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BASEL   (Switzerland)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ARGININE; CD4 ANTIGEN; GLYCOPROTEIN GP 120; PHENYLALANINE; PROTEIN INHIBITOR; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL FUSION; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

AMIDINES; ANTI-HIV AGENTS; ANTIGENS, CD4; DRUG DESIGN; GUANIDINE; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV-1; HUMANS; MEMBRANE FUSION; MOLECULAR MIMICRY; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1942470110     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.02.091     Document Type: Article

References (27)

1. http://www.WHO.org
2. Cooley L.A., Lewin S.R. J. Clin. Virol. 2002;1-12.
3. Dalgeish A.G., Beverley P.C., Clapham P.R., Crawford D.H. Nature. 312:1984;763-767.
4. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., Sodroski J.G. Nature. 393:1998;705-711.
5. LaBranche C.C., Galasso G., Moore J.P., Bolognesi D.P., Hirsch M.S. Antiviral Res. 50:2001;95-115.
6. Yachou A., Sékaly R.P. Biochem. Biophys. Res. Commun. 265:1999;428-433.
7. Jiang S.B., Zhao Q., Debnath A.K. Curr. Pharm. Des. 8:2002;563-580.
8. Tremblay C.L., Giguel F., Kollmann C., Guan Y.B., Chou T.C.et al. Antimicrob. Agents Chemother. 46:2002;1336-1339.
9. Tamamura H., Omagari A., Oishi S., Kanamoto T., Yamamoto N., Peiper S.C., Nakashima H., Otaka A., Fujii N. Bioorg. Med. Chem. Lett. 10:2000;2633-2637.
10. Ruff M.R., Melendez-Guerrero L.M., Yang Q., Ho W., Mikovits J.W.et al. Antiviral Res. 52:2001;63-75.
11. Fletcher C.V. The Lancet. 361:2003;1577-1578.
12. Labonte J., Lebbos J., Kirkpatrick P. Nature Rev. Drug Discov. 2:2003;345-346.
13. Toogood P.L. J. Med. Chem. 45:2002;1543-1558.
14. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Nature. 393:1998;648-659.
15. Moore J.P., Binley J. Nature. 393:1998;630-631.
16. Boussard C., Doyle V.E., Mahmood N., Klimkait T., Pritchard M., Gilbert I.H. Eur. J. Med. Chem. 37:2002;883-890.
17. Magalhes A., Monteiro M.R., Magalhes H.P., Mares-Guia L., Rogana E. Toxicon. 35:1997;1549-1559.
18. 13C, mass spectrometry and accurate mass analysis.
19. Yong Y.F., Kowalski J.A., Lipton M.A. J. Org. Chem. 62:1997;1540-1542.
20. Bernatowicz M.S., Wu Y., Matsueda G.R. Tetrahedron Lett. 34:1993;3389-3392.
21. Miel H., Rault S. Tetrahedron Lett. 39:1998;1565-1568.
22. Greene T.W., Peter G.M. Protective Groups in Organic Synthesis. 2nd ed. 1991;Wiley-Interscience, New York, USA.
23. Miel H., Rault S. Tetrahedron Lett. 38:1997;7865-7866.
24. Findlay J.A., Tang C.S. Can. J. Chem. 45:1967;1014-1015.
25. Lappert M.F., Slade M.J., Singh A. J. Am. Chem. Soc. 105:1983;302-304.
26. Klimkait T., Stauffer F., Lupo E., Sonderegger-Rubli C. Arch. Virol. 143:1998;2109.
27. Karn J. HIV, Biochemistry, Molecular Biology and Drug Discovery. Vol. 2:1995;Oxford University Press, New York, USA.